CX-4945 in Viral Community Acquired Pneumonia

NCT06202521 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped The trial ended early in March 2025 due to changes in disease epidemiology, affecting patient availability and recruitment feasibility.

Conditions

Community-acquired Pneumonia
SARS-CoV-2 -Associated Pneumonia
Influenza With Pneumonia

Interventions

DRUG: CX-4945 (SARS-CoV-2 domain)
DRUG: Placebo (SARS-CoV-2 domain)
DRUG: CX-4945 (Influenza virus domain)
DRUG: Placebo (Influenza virus domain)

Sponsor

Senhwa Biosciences, Inc.